[1]
|
Kulik, L. and El-Serag, H. B. (2019) Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology, 156, 477-491. https://doi.org/10.1053/j.gastro.2018.08.065
|
[2]
|
Llovet, J.M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.F. and Bruix, J. (2008) Sorafenib in Advanced Hepatocellular Carcinoma. New England Journal of Medicine, 359, 378-390. https://doi.org/10.1056/NEJMoa0708857
|
[3]
|
Boland, P. and Wu, J. (2018) Systemic Therapy for Hepatocellular Carcinoma: Beyond Sorafenib. Chinese Clinical Oncology, 7, 50. https://doi.org/10.21037/cco.2018.10.10
|
[4]
|
Finn, R.S., Qin, S., Ikeda, M., Galle, P.R., Ducreux, M., Kim, T.Y. and Cheng, A.L. (2020) Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. New England Journal of Medicine, 382, 1894-1905.
https://doi.org/10.1056/NEJMoa1915745
|
[5]
|
Hanahan, D. and Weinberg, R.A. (2011) Hallmarks of Cancer: The Next Generation. Cell, 144, 646-674.
https://doi.org/10.1016/j.cell.2011.02.013
|
[6]
|
Miranda-Zazueta, G., de Leon-Garduno, L.A.P., Aguirre-Valadez, J. and Torre-Delgadillo, A. (2020) Bacterial Infections in Cirrhosis: Current Treatment. Annals of Hepatology, 19, 238-244. https://doi.org/10.1016/j.aohep.2019.09.011
|
[7]
|
Okusaka, T. and Ikeda, M. (2018) Immunotherapy for Hepato-cellular Carcinoma: Current Status and Future Perspectives. ESMO Open, 3, e000455. https://doi.org/10.1136/esmoopen-2018-000455
|
[8]
|
Zhang, P., Wang, Y., Mei, W. and Zeng, C. (2022) Over-coming Resistance to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Challenges and Opportunities. Fron-tiers in Oncology, 12, Article ID: 958720.
https://doi.org/10.3389/fonc.2022.958720
|
[9]
|
Shen, W., Chen, Y., Lei, P., Sheldon, M., Sun, Y., Yao, F. and Ma, L. (2022) Immunotherapeutic Approaches for Treating Hepatocellular Carcinoma. Cancers, 14, 5013. https://doi.org/10.3390/cancers14205013
|
[10]
|
Keir, M.E., Butte, M.J., Freeman, G.J. and Sharpe, A.H. (2008) PD-1 and Its Ligands in Tolerance and Immunity. Annual Review of Immunology, 26, 677-704. https://doi.org/10.1146/annurev.immunol.26.021607.090331
|
[11]
|
Lu, C., Rong, D., Zhang, B., Zheng, W., Wang, X., Chen, Z. and Tang, W. (2019) Current Perspectives on the Immunosuppressive Tumor Microenvironment in Hepa-tocellular Carcinoma: Challenges and Opportunities. Molecular Cancer, 18, 1-12. https://doi.org/10.1186/s12943-019-1047-6
|
[12]
|
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T. and Min-ato, N. (2002) Involvement of PD-L1 on Tumor Cells in the Escape from Host Immune System and Tumor Immuno-therapy by PD-L1 Blockade. Proceedings of the National Academy of Sciences, 99, 12293-12297. https://doi.org/10.1073/pnas.192461099
|
[13]
|
Jain, N., Nguyen, H., Chambers, C. and Kang, J. (2010) Dual Func-tion of CTLA-4 in Regulatory T Cells and Conventional T Cells to Prevent Multiorgan Autoimmunity. Proceedings of the National Academy of Sciences, 107, 1524-1528.
https://doi.org/10.1073/pnas.0910341107
|
[14]
|
Seidel, J.A., Otsuka, A. and Kabashima, K. (2018) Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations. Frontiers in Oncology, 8, 86. https://doi.org/10.3389/fonc.2018.00086
|
[15]
|
Twyman-Saint Victor, C., Rech, A.J., Maity, A., Rengan, R., Pauken, K.E., Stelekati, E. and Minn, A.J. (2015) Radiation and Dual Checkpoint Blockade Activate Non-Redundant Immune Mechanisms in Cancer. Nature, 520, 373-377.
https://doi.org/10.1038/nature14292
|
[16]
|
Egen, J.G., Kuhns, M.S. and Allison, J.P. (2002) CTLA-4: New Insights into Its Biological Function and Use in Tumor Immunotherapy. Nature Immunology, 3, 611-618. https://doi.org/10.1038/ni0702-611
|
[17]
|
袁声贤, 周伟平. 原发性肝癌综合治疗的进展和热点. 中华消化外科杂志, 2021, 20(2): 163-170.
|
[18]
|
Li, N., Feng, S., Xue, J., Wei, X.B., Shi, J., Guo, W.X., Lau, W.Y., Wu, M.C., Cheng, S.Q. and Meng, Y. (2016) Hepatocellular Carcinoma with Main Portal Vein Tumor Thrombus: A Comparative Study Comparing Hepatectomy with or without Neoadjuvant Radiotherapy. HPB, 18, 549-556. https://doi.org/10.1016/j.hpb.2016.04.003
|
[19]
|
Wei, X., Jiang, Y., Zhang, X., Feng, S., Zhou, B., Ye, X., Xing, H., Xu, Y., Shi, J., Guo, W., Zhou, D., Zhang, H., Sun, H., Huang, C., Lu, C., Zheng, Y., Meng, Y., Huang, B., Cong, W., Lau, W.Y. and Cheng, S. (2019) Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Randomized, Open-Label, Multicenter Controlled Study. Journal of Clinical Oncology, 37, 2141-2151.
https://doi.org/10.1200/JCO.18.02184
|
[20]
|
Wu, F., Chen, B., Dong, D., Rong, W., Wang, H., Wang, L., Wang, S., Jin, J., Song, Y., Liu, Y., Fang, H., Tang, Y., Li, N., Zhu, X., Li, Y., Wang, W. and Wu, J. (2022) Phase 2 Evaluation of Neoadjuvant Intensity-Modulated Radiotherapy in Centrally Located Hepatocellular Carcinoma: A Nonrandomized Con-trolled Trial. JAMA Surgery, 157, 1089-1096.
https://doi.org/10.1001/jamasurg.2022.4702
|
[21]
|
Marron, T.U., Fiel, M.I., Hamon, P., Fiaschi, N., Kim, E., Ward, S.C. and Merad, M. (2022) Neoadjuvant Cemiplimab for Resectable Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase 2 Trial. The Lancet Gastroenterology & Hepatology, 7, 219-229. https://doi.org/10.1016/S2468-1253(21)00385-X
|
[22]
|
Wei, F. (2022) Neoadjuvant Immunotherapy for Resectable Hepatocellular Carcinoma. The Lancet Gastroenterology & Hepatology, 7, 504. https://doi.org/10.1016/S2468-1253(22)00083-8
|
[23]
|
Kaseb, A.O., Hasanov, E., Cao, H.S.T., Xiao, L., Vauthey, J.N., Lee, S.S. and Sharma, P. (2022) Perioperative Nivolumab Monotherapy versus Nivolumab plus Ipilimumab in Re-sectable Hepatocellular Carcinoma: A Randomised, Open-Label, Phase 2 Trial. The Lancet Gastroenterology & Hepa-tology, 7, 208-218.
https://doi.org/10.1016/S2468-1253(21)00427-1
|
[24]
|
Xia, Y., Tang, W., Qian, X., Li, X., Cheng, F., Wang, K. and Wang, X. (2022) Efficacy and Safety of Camrelizumab plus Apatinib during the Perioperative Period in Resectable Hepatocellular Carcinoma: A Single-Arm, Open Label, phase II Clinical Trial. Journal for Immunotherapy of Cancer, 10, e004656. https://doi.org/10.1136/jitc-2022-004656
|
[25]
|
Shi, Y.H., Ji, Y., Liu, W.R., Pang, Y.R., Ding, Z.B., Fu, X.T. and Fan, J. (2021) A Phase Ib/II, Open-Label Study Evaluating the Efficacy and Safety of Toripalimab Injection (JS001) or Combination with Lenvatinib as a Neoadjuvant Therapy for Patients with Resectable Hepatocellular Carcino-ma (HCC). Cancer Research, 81, 486-486.
https://doi.org/10.1158/1538-7445.AM2021-486
|
[26]
|
Yarchoan, M., Zhu, Q., Durham, J.N., Gross, N., Charmsaz, S., Leatherman, J.M. and Ho, W.J. (2021) Feasibility and Efficacy of Neoadjuvant Cabozantinib and Nivolumab in Pa-tients with Borderline Resectable or Locally Advanced Hepatocellular Carcinoma (HCC). Journal of Clinical Oncology, 39, 335-335.
https://doi.org/10.1200/JCO.2021.39.3_suppl.335
|
[27]
|
Duffy, A.G., Ulahannan, S.V., Makorova-Rusher, O., Rahma, O., Wedemeyer, H., Pratt, D. and Greten, T.F. (2017) Tremelimumab in Combination with Ablation in Patients with Advanced Hepatocellular Carcinoma. Journal of Hepatology, 66, 545-551. https://doi.org/10.1016/j.jhep.2016.10.029
|
[28]
|
Reynders, K., Illidge, T., Siva, S., Chang, J.Y. and De Ruysscher, D. (2015) The Abscopal Effect of Local Radiotherapy: Using Immunotherapy to Make a Rare Event Clinically Relevant. Cancer Treatment Reviews, 41, 503-510.
https://doi.org/10.1016/j.ctrv.2015.03.011
|
[29]
|
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Cri-ollo, A. and Zitvogel, L. (2007) Toll-Like Receptor 4-Dependent Contribution of the Immune System to Anticancer Chemotherapy and Radiotherapy. Nature Medicine, 13, 1050-1059. https://doi.org/10.1038/nm1622
|
[30]
|
Chang, Y., Jeong, S.W., Young Jang, J. and Jae Kim, Y. (2020) Recent Updates of Transarterial Chemoembolilzation in Hepatocel-lular Carcinoma. International Journal of Molecular Sciences, 21, 8165.
https://doi.org/10.3390/ijms21218165
|
[31]
|
Kudo, M. (2019) Immuno-Oncology Therapy for Hepatocellular Carci-noma: Current Status and Ongoing Trials. Liver Cancer, 8, 221-238. https://doi.org/10.1159/000501501
|
[32]
|
Kudo, M. (2017) Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials. Oncology, 92, 50-62. https://doi.org/10.1159/000451016
|
[33]
|
Pinato, D.J., Murray, S.M., Forner, A., Kaneko, T., Fessas, P., To-niutto, P. and Mazzaferro, V. (2021) Trans-Arterial Chemoembolization as a Loco-Regional Inducer of Immunogenic Cell Death in Hepatocellular Carcinoma: Implications for Immunotherapy. Journal for Immunotherapy of Cancer, 9, e003311. https://doi.org/10.1136/jitc-2021-003311
|
[34]
|
Sharma, P., Hu-Lieskovan, S., Wargo, J.A. and Ribas, A. (2017) Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell, 168, 707-723. https://doi.org/10.1016/j.cell.2017.01.017
|
[35]
|
Brandsma, D. and van den Bent, M.J. (2009) Pseudoprogression and Pseudoresponse in the Treatment of Gliomas. Current Opinion in Neurology, 22, 633-638. https://doi.org/10.1097/WCO.0b013e328332363e
|
[36]
|
Rocha, P., Hardy-Werbin, M., Naranjo, D., Taus, Á., Ro-drigo, M., Zuccarino, F. and Arriola, E. (2018) CD103+ CD8+ Lymphocytes Characterize the Immune Infiltration in a Case with Pseudoprogression in Squamous NSCLC. Journal of Thoracic Oncology, 13, e193-e196. https://doi.org/10.1016/j.jtho.2018.05.008
|
[37]
|
Zhou, H. and Song, T. (2021) Conversion Therapy and Mainte-nance Therapy for Primary Hepatocellular Carcinoma. BioScience Trends, 15, 155-160. https://doi.org/10.5582/bst.2021.01091
|
[38]
|
Qiao, Z.Y., Zhang, Z.J., Lv, Z.C., Tong, H., Xi, Z.F., Wu, H.X. and Xia, Q. (2021) Neoadjuvant Programmed Cell Death 1 (PD-1) Inhibitor Treatment in Patients with Hepatocellular Carci-noma before Liver Transplant: A Cohort Study and Literature Review. Frontiers in Immunology, 12, Article ID: 653437. https://doi.org/10.3389/fimmu.2021.653437
|